Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Tables)

v3.22.2
Non-Controlling Interests (Tables)
6 Months Ended
Jun. 30, 2022
Non-Controlling Interests  
Schedule of Non-Controlling Interests in Consolidated Entities

Non-controlling interests in consolidated entities are as follows:

​

​

​

​

​

​

​

​

​

​

​

For the Six Months Ended

    

    

​

    

    

 

​

June 30, 2022

​

As of June 30, 2022

​

​

 

​

Net loss attributable to

​

Non-controlling interests

​

Non-controlling

 

($ in thousands)

non-controlling interests

​

in consolidated entities

​

ownership

 

UR-1

$

(482)

​

$

(664)

 

34.5

%

Aevitas

 

(341)

​

 

(5,555)

 

45.9

%

Avenue 2

 

(2,576)

​

 

495

 

82.8

%

Baergic

 

(136)

​

 

(2,267)

 

39.0

%

Cellvation

 

(110)

​

 

(1,691)

 

21.7

%

Checkpoint 1

 

(25,007)

​

 

6,009

 

80.5

%

Coronado SO

 

—

​

 

(290)

 

13.0

%

Cyprium

 

(421)

​

 

(2,803)

 

29.0

%

Helocyte

 

(184)

​

 

(5,655)

 

17.9

%

JMC

 

(3,302)

​

 

17,723

 

50.9

%

Mustang 2

 

(33,580)

​

 

67,212

 

82.0

%

Oncogenuity

 

(139)

​

 

(1,277)

 

24.5

%

Tamid

 

(14)

​

 

(758)

 

22.8

%

Total

$

(66,292)

​

$

70,479

 

  

​

​

​

​

​

​

​

​

​

​

​

​

For the Year Ended

​

    

​

​

    

 

​

December 31, 2021

​

As of December 31, 2021

​

​

 

​

Net loss attributable to 

​

Non-controlling interests 

​

Non-controlling 

 

($ in thousands)

non-controlling interests

    

 in consolidated entities

    

 ownership

 

UR-1

​

(1,353)

​

$

(1,795)

 

34.5

%

Aevitas

​

(901)

​

 

(5,060)

 

45.9

%

Avenue 2

​

(2,909)

​

 

2,830

 

82.0

%

Baergic

​

(39)

​

 

(2,086)

 

39.0

%

Cellvation

​

(131)

​

 

(1,544)

 

21.7

%

Checkpoint 1

​

(39,226)

​

 

24,238

 

81.5

%

Coronado SO

​

—

​

 

(290)

 

13.0

%

Cyprium

​

(807)

​

 

(2,204)

 

29.8

%

Helocyte

​

(89)

​

 

(5,529)

 

18.3

%

JMC

​

(5,652)

​

 

17,498

 

41.6

%

Mustang 2

​

(48,518)

​

 

93,009

 

82.7

%

Oncogenuity

​

(497)

​

 

(1,124)

 

24.9

%

Tamid

​

(1)

​

 

(740)

 

22.8

%

Total

$

(100,123)

​

$

117,203

 

​

​

​

Note 1:

Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Note 2:

Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.